Warning Letter Record: AHC Products, Inc. (2026-06-12) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
In short: On June 12, 2026, the FDA's Center for Veterinary Medicine issued a warning letter to AHC Products, Inc. (Winchester, KY) following an October 20–23, 2025 inspection, citing significant CGMP violations under 21 CFR parts 210 and 211 for finished pharmaceuticals, rendering products adulterated under FD&C Act § 501(a)(2)(B). The firm failed to conduct required laboratory testing prior to release for multiple products including a wound dressing and AniPrin aspirin formulations—instead relying on visual color comparison and unvalidated methodologies—and falsely reported microbiological and heavy metal testing on Certificates of Analysis without performing the actual tests; the FDA also cited marketing of unapproved new animal drugs including AniPrin P and Rot-B-Gone.
Argus analysis
# FDA Warning Letter Analysis: AHC Products, Inc.
**Company and Findings**
AHC Products, Inc., located in Winchester, Kentucky, received a CGMP warning letter from FDA's Center for Veterinary Medicine on June 12, 2026, following an inspection conducted October 20–23, 2025. The agency found that the firm's manufacturing methods, facilities, and controls for finished animal pharmaceuticals do not conform to Current Good Manufacturing Practice regulations, rendering its drug products adulterated. The warning also addresses marketing of unapproved new animal drugs, including products identified as AniPrin P, AniPrin LQ, and Rot-B-Gone.
**Regulatory Citations and Compliance Context**
The violations center on 21 CFR parts 210 and 211, which establish CGMP standards for pharmaceutical manufacturing. Specifically, AHC Products violated 21 CFR 211.165(a) by releasing finished drug products without appropriate laboratory testing to confirm identity and strength of active ingredients. The firm also violated 21 CFR 211.84(d) by failing to test incoming components for identity and conformity with written specifications. These sections represent foundational requirements: finished product release testing verifies that batches meet established quality standards before distribution, while component testing prevents use of unsuitable raw materials. FDA's position emphasizes that visual assessment and unvalidated analytical methods cannot substitute for rigorous, quantitative laboratory testing. Relying on supplier certificates of analysis alone, without independent verification, does not satisfy regulatory expectations.
**Response Timeline and Industry Expectations**
AHC Products submitted a response to FDA's Form 483 on November 13, 2025, which FDA found inadequate. The firm now must provide a comprehensive remediation plan addressing laboratory practices, validated testing methods, and retrospective testing of all distributed product lots still within expiry. Peer compliance officers in veterinary pharmaceutical manufacturing should monitor whether AHC Products implements validated analytical methods within stated timelines, establishes qualified third-party laboratory relationships, and initiates product recalls if retained sample testing reveals substandard quality. The adequacy of the firm's corrective action response and FDA's subsequent inspection will indicate enforcement trajectory.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER AHC Products, Inc. MARCS-CMS 728604 — June 12, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Animal & Veterinary Drugs Recipient: Recipient Name Mr. Michael Wolf Recipient Title Compliance Manager and Pharmacist in Charge AHC Products, Inc. 301 W Broadway St Winchester , KY 40391-1915 United States Issuing Office: Center for Veterinary Medicine United States June 12, 2026 CMS Case: 728604 WARNING LETTER Dear Mr. Wolf: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, AHC Products, Inc., located at 301 W Broadway St, Winchester, KY from October 20 to 23, 2025. This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)]. In addition, this letter concerns your firm’s marketing of several unapproved new animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The specific products include (b)(4) , AniPrin P, and Rot-B-Gone. Current Good Manufacturing Practice Violations We reviewed your November 13, 2025, response to our Form FDA 483 in detail. We have not received any other correspondence from you regarding the inspection. Our review of the evidence gathered during the inspection and your response revealed significant violations, including the following. 1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)). Your firm manufactures drug products, including (b)(4) wound dressing and Animed AniPrin liquid and powder aspirin products (AniPrin LQ and AniPrin P). Your firm failed to ensure that testing and release of drug products for distribution included appropriate laboratory determination of satisfactory conformance to final specifications prior to release. For example, your firm released (b)(4) lots of (b)(4) without conducting any finished product laboratory testing. Your firm's product release decisions for these lots were based solely on visual assessment of (b)(4) properties. Additionally, your firm listed test results for microbiological hazards and heavy metal content on Certificates of Analysis (COAs) for all manufactured lots of AniPrin F, AniPrin LQ, AniPrin LQ with Caffeine, and AniPrin P without performing the corresponding analytical testing on the finished product batches. In your response, you stated that fo…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has AHC Products, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for AHC Products, Inc. as of 2026-07-28. Argus ingests new FDA enforcement records daily.
- What FDA violations was AHC Products, Inc. cited for?
- The FDA Warning Letter to AHC Products, Inc. (issuing office: Center for Veterinary Medicine) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to AHC Products, Inc.?
- FDA issued the letter (MARCS-CMS 728604) on 2026-06-12 and posted it publicly on fda.gov on 2026-07-28.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: AHC Products, Inc. (2026-06-12) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-ahc-products-inc-2026-06-12-cgmp
"Warning Letter Record: AHC Products, Inc. (2026-06-12) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-ahc-products-inc-2026-06-12-cgmp.
Argus HQ Research. "Warning Letter Record: AHC Products, Inc. (2026-06-12) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed July 29, 2026. https://argushq.ai/fda/warning-letter/fda-wl-ahc-products-inc-2026-06-12-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_ahc_products_inc_2026_06_12_cgmp_2026,
title = {Warning Letter Record: AHC Products, Inc. (2026-06-12) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-ahc-products-inc-2026-06-12-cgmp},
note = {Accessed: July 29, 2026}
}